Novel actions of antidepressant and antipsychotic drugs

DOI Web Site
  • Odagaki Yuji
    Department of Psychiatry, Faculty of Medicine, Saitama Medical University

Bibliographic Information

Other Title
  • 抗うつ薬および抗精神病薬の新たな作用
  • アラガウツ クスリ オヨビ コウセイシンビョウヤク ノ アラタ ナ サヨウ

Search this article

Abstract

Symposium-77 took place under the title ‘Novel actions of antidepressant and antipsychotic drugs’, chaired by Drs. Garcia-Sevilla and Odagaki. The four speakers made presentation of their own interesting data. 1) Dr. Yamada showed the behavioral pharmacological and biochemical data on riluzole, a promising antidepressant/anxiolytic agent with novel mechanisms of action. 2) Dr. Takebayashi demonstrated that antidepressants such as amitriptyline acted directly on glial cells to result in GDNF (glial cell line-derived neurotrophic factor) production, which was mediated through multiple molecular cascades related to fibroblast growth factor receptor (FGFR) signaling. 3) Dr. González-Maeso noticed that histone deacetylases (HDACs) played a pivotal role as an epigenetic regulator of metabotropic glutamate receptor 2 (mGlu2) in the treatment with atypical antipsychotics, and provided the view that HDAC2 might be a novel therapeutic target to improve the antipsychotic efficacy. 4) Dr. Garcia-Sevilla showed the implications of Fas-associated death domain (FADD) in pathogenesis of major depressive disorders and mechanisms of action of antidepressants. The psychotropic drugs available at present are at most modifications of prototypal ones that had been empirically found more than a half century ago. The author believes that this symposium must contribute to the new concepts for developing drugs with novel mechanisms of action.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top